全球炭疽菌疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計炭疽菌疫苗市場將從 2025 年的 188.2 億美元成長到 2034 年的 315 億美元，2026 年至 2034 年的複合年成長率為 5.89%。

在全球對生物威脅的認知不斷提高以及對醫療保健措施的需求日益成長的推動下，全球炭疽菌疫苗市場正穩步成長。炭疽菌是由炭疽菌引起的一種嚴重感染疾病，接種疫苗被認為是最有效的預防措施之一。各國政府和國防機構正積極投資疫苗儲備，以保護相關人員和公眾免受潛在生物威脅。

推動市場成長的因素包括政府加強緊急準備計畫和生物防禦研究。醫療衛生機構和公共衛生機構正在強化疫苗接種策略，以應對潛在的疫情爆發和生物恐怖主義風險。此外，疫苗研發技術的進步也提高了炭疽菌疫苗的安全性和有效性。

由於對生物防禦研發和疫苗創新持續投入，炭疽菌疫苗市場預計未來將持續成長。新一代疫苗的研發有望提高疫苗的穩定性並降低用量，從而增強對該疾病的保護作用。鑑於全球衛生安全仍是重中之重，預計炭疽菌疫苗的需求將保持穩定。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球炭疽菌疫苗市場：按類型分類

• 市場分析、洞察與預測
• 無細胞PA疫苗
• 減毒活病毒疫苗

第5章 全球炭疽菌疫苗市場：依應用分類

• 市場分析、洞察與預測
• 獸用
• 對人類而言

第6章 全球炭疽菌疫苗市場：依最終用途分類

• 市場分析、洞察與預測
• 獸醫醫院和診所
• 醫院和診所
• 其他最終用戶

第7章 全球炭疽菌疫苗市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Altimmune Inc
  • Godrej Agrovet Limited
  • Bayer AG
  • Bavarian Nordic A/S
  • Biogenesis Bago SA
  • Ceva SantAfA（C）Animale
  • Colorado Serum Company
  • Emergent BioSolutions
  • Elusys Therapeutics Inc
  • Indian Immunologicals Ltd
  • Intervac（PVT）Ltd
  • JOVAC（Jordan BioIndustries Center）
  • Merck & Co. Inc
  • Proton Biopharma Ltd

The Anthrax Vaccine Market size is expected to reach USD 31.50 Billion in 2034 from USD 18.82 Billion (2025) growing at a CAGR of 5.89% during 2026-2034.

The Global Anthrax Vaccine Market is growing steadily due to increasing awareness of biological threats and the need for preventive healthcare measures. Anthrax is a serious infectious disease caused by the bacterium Bacillus anthracis, and vaccination is considered one of the most effective methods of prevention. Governments and defense organizations are actively investing in vaccine stockpiling to protect military personnel and civilian populations from potential biological threats.

Several factors are driving market growth, including government preparedness programs and increased research in biodefense. Healthcare authorities and public health agencies are strengthening vaccination strategies to respond to potential outbreaks or bioterrorism risks. Additionally, advancements in vaccine development technologies are improving the safety and effectiveness of anthrax vaccines.

In the future, the anthrax vaccine market is expected to expand with continued investments in biodefense research and vaccine innovation. The development of next-generation vaccines with improved stability and reduced dosing requirements may enhance protection against the disease. As global health security remains a priority, demand for anthrax vaccines is likely to remain stable.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Cell Free PA Vaccine
• Live Attenuated Vaccine

By Application

• Veterinary Use
• Human Use

By End-use

• Veterinary Hospitals & Clinics
• Hospital & Clinics
• Other End-users

COMPANIES PROFILED

• Altimmune Inc, Godrej Agrovet Limited, Bayer AG, Bavarian Nordic AS, Biogenesis Bago SA, Ceva Sant Animale, Colorado Serum Company, Emergent BioSolutions, Elusys Therapeutics Inc, Indian Immunologicals Ltd, Intervac PVT Ltd, JOVAC Jordan BioIndustries Center, Merck Co Inc, Proton Biopharma Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTHRAX VACCINE MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Cell Free PA Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Live Attenuated Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL ANTHRAX VACCINE MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Veterinary Use Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Human Use Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL ANTHRAX VACCINE MARKET: BY END-USE 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Veterinary Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Hospital & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Other End-users Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL ANTHRAX VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTHRAX VACCINE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Altimmune Inc
  • 9.2.2 Godrej Agrovet Limited
  • 9.2.3 Bayer AG
  • 9.2.4 Bavarian Nordic A/S
  • 9.2.5 Biogenesis Bago S.A
  • 9.2.6 Ceva SantAfA(C) Animale
  • 9.2.7 Colorado Serum Company
  • 9.2.8 Emergent BioSolutions
  • 9.2.9 Elusys Therapeutics Inc
  • 9.2.10 Indian Immunologicals Ltd
  • 9.2.11 Intervac (PVT) Ltd
  • 9.2.12 JOVAC (Jordan BioIndustries Center)
  • 9.2.13 Merck & Co. Inc
  • 9.2.14 Proton Biopharma Ltd